969 related articles for article (PubMed ID: 35113333)
1. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.
Bailey CJ; Day C; Bellary S
Curr Diab Rep; 2022 Jan; 22(1):39-52. PubMed ID: 35113333
[TBL] [Abstract][Full Text] [Related]
2. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
3. Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.
Thomson SC; Vallon V
Am J Cardiol; 2019 Dec; 124 Suppl 1(Suppl 1):S28-S35. PubMed ID: 31741437
[TBL] [Abstract][Full Text] [Related]
4. A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review.
Song J; Li X; Ni J
Kidney Blood Press Res; 2023; 48(1):599-610. PubMed ID: 37717569
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of sodium-glucose cotransporter 2 to slow the progression of chronic kidney disease.
Oguz F; Demoulin N; Thissen JP; Jadoul M; Morelle J
Acta Clin Belg; 2022 Aug; 77(4):805-814. PubMed ID: 34404335
[TBL] [Abstract][Full Text] [Related]
6. Modeling the renoprotective mechanisms of SGLT2 inhibition in hypertensive chronic kidney disease.
Clemmer JS; Yen TE; Obi Y
Physiol Rep; 2023 Nov; 11(21):e15836. PubMed ID: 37957121
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
[TBL] [Abstract][Full Text] [Related]
8. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
Cruz JE; Ahuja T; Bridgeman MB
Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
[TBL] [Abstract][Full Text] [Related]
9. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
10. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
Thomas MC; Cherney DZI
Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 Inhibitors in Kidney Diseases-A Narrative Review.
Gajewska A; Wasiak J; Sapeda N; Młynarska E; Rysz J; Franczyk B
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732178
[TBL] [Abstract][Full Text] [Related]
12. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence.
Davidson JA
Postgrad Med; 2019 May; 131(4):251-260. PubMed ID: 30929540
[TBL] [Abstract][Full Text] [Related]
13. The tubular hypothesis of nephron filtration and diabetic kidney disease.
Vallon V; Thomson SC
Nat Rev Nephrol; 2020 Jun; 16(6):317-336. PubMed ID: 32152499
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
15. Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.
Zhang Y; Thai K; Kepecs DM; Gilbert RE
PLoS One; 2016; 11(1):e0144640. PubMed ID: 26741142
[TBL] [Abstract][Full Text] [Related]
16. SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism.
Layton AT; Vallon V
Am J Physiol Renal Physiol; 2018 May; 314(5):F969-F984. PubMed ID: 29361669
[TBL] [Abstract][Full Text] [Related]
17. Diabetes and Cardiorenal Complications: A Clinical Review of Existing Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors.
Kale A; Sharma A; Anders HJ; Gaikwad AB
Curr Diabetes Rev; 2023; 19(8):e160822207546. PubMed ID: 35975848
[TBL] [Abstract][Full Text] [Related]
18. Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis.
Koh ES; Kim GH; Chung S
Endocrinol Metab (Seoul); 2023 Aug; 38(4):359-372. PubMed ID: 37482684
[TBL] [Abstract][Full Text] [Related]
19. Kidney outcomes of SGLT2 inhibitors among older patients with diabetic kidney disease in real-world clinical practice: the Japan Chronic Kidney Disease Database Ex.
Kitaoka K; Yano Y; Nagasu H; Kanegae H; Chishima N; Akiyama H; Tamura K; Kashihara N
BMJ Open Diabetes Res Care; 2024 May; 12(3):. PubMed ID: 38816204
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 inhibition and kidney protection.
Nespoux J; Vallon V
Clin Sci (Lond); 2018 Jun; 132(12):1329-1339. PubMed ID: 29954951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
